Depot-medroxyprogesterone acetate in anticoagulated patients with previous hemorrhagic corpus luteum

European Journal of Contraception and Reproductive Health Care

Volumn 10, Issue 1, 2005, Pages 9-14

  Sonmezer M ^a   Atabekoglu C ^a   Cengiz, B ^a   Dokmeci F ^a   Cengiz, S D ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Chronic anticoagulation; Corpus hemorrghagicum; Depot medroxyprogesterone acetate; Ovulation

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CARBAMAZEPINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE ACETATE; MEFENAMIC ACID; TRIACYLGLYCEROL; WARFARIN;

ADULT; ANTICOAGULATION; ARTICLE; BLOATING; BODY WEIGHT; BREAKTHROUGH BLEEDING; BREAST TENDERNESS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CORPUS LUTEUM HEMORRHAGICUM; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HEADACHE; HEART VALVE PROSTHESIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; LUTEAL INSUFFICIENCY; OVARIAN BLEEDING; OVULATION INHIBITION; PATIENT MONITORING; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTICOAGULANTS; CONTRACEPTIVE AGENTS; CORPUS LUTEUM; DELAYED-ACTION PREPARATIONS; DRUG INTERACTIONS; FEMALE; FOLLOW-UP STUDIES; HEART VALVE PROSTHESIS; HEMORRHAGE; HUMANS; INJECTIONS, INTRAMUSCULAR; MEDROXYPROGESTERONE 17-ACETATE; PROBABILITY; PROSPECTIVE STUDIES; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 20344396602     PISSN: 13625187     EISSN: None     Source Type: Journal    
DOI: 10.1080/13625180400020952     Document Type: Article

References (28)

1. McMahan DA, Smith DM, Carey MA, et al. Risk of major hemorrhage for outpatients treated with warfarin. J Gen Intern Med 1998;13:311-16.
2. Euhus DM, Hiatt JR. Management of the acute abdomen complicating oral anticoagulation therapy. Am Surg 1990;56:581-6.
3. Ghosh K, Mohanty D, Pathare AV, et al. Recurrent haemoperitoneum in a female patient with type III von Willebrand's disease responded to administration of oral contraceptive. Haemophilia 1998;4:767-8.
4. Tanaka T. Non-operative management of idiopathic ovarian hemorrhage with massive intraabdominal hemorrhage. Osaka City Med J 1997;43:7-14
5. Ulrich U, Rossmanith WG. Management of peritoneal hemorrhage due to follicle rupture under anticoagulation therapy. J Endocrinol Invest 1994;17:351-3.
6. Peters WA, Thiagarajah S, Thornton WN. Ovarian hemorrhage in patients receiving anticoagulant therapy. J Reprod Med 1979;22:82-6.
7. Wong KP, Gillett PG. Recurrent hemorrhage from corpus luteum during anticoagulant therapy. Can Med Assoc J 1977;116:388-90.
8. Hill JA, Kassam SH. Ovarian hemorrhage in ovulating women receiving anticoagulant therapy. A report of two cases. J Reprod Med 1984;29:205-8.
9. Jarvis RR, Olsen ME. Type I von Willebrand's disease presenting as recurrent corpus hemorrhagicum. Obstet Gynecol 2002;99(5 Pt 2):887-8.
10. Mishell DR Jr. Cardiovascular risks: perception versus reality. Contraception 1999;59(Supp 1):21S-24S.
11. Fotherby K, Koetsawang S, Mathrubutham M. Pharmacokinetic study of different doses of Depo Provera. Contraception 1980;22:527-36.
12. Multinational comparative clinical trial of long-acting injectable contraceptives: norethisterone enanthate given in two dosage regimens and depot-medroxyprogesterone acetate. Contraception 1983;28:1-20.
13. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. Contraception 1998;57:315-24.
14. Gomez A, Lucia JF, Perella M, et al. Haemoperitoneum caused by haemorrhagic corpus luteum in a patient with type 3 von Willebrand's disease. Haemophilia 1998;4:60-2.
15. Weseley AC, Neustadter MI, Levine MW. Massive intraperitoneal hemorrhage of ovarian follicular origin during anticoagulant therapy. Am J Obstet Gynecol 1957;73:683-5.
16. Dunn AS, Turpie AG. Perioperative management of patients receiving oral anticoagulants: a systematic review. Arch Intern Med 2003;163:901-8.
17. Baglin T. Management of warfarin (coumarin) overdose. Blood Rev 1998;12:91-8.
18. Lurie S, Katz Z, Konichezky S, Borenstein R. Conservative approach to massive haemoperitoneum of ovarian origin during anticoagulant therapy. Clin Exp Obstet Gynecol 1991;18:263-4.
19. Bottini E, Pareti FI, Mari D, Mannucci PM, et al. Prevention of hemoperitoneum during ovulation by oral contraceptives in women with type III von Willebrand disease and afibrinogenemia. Case reports. Haematologica 1991;76:431-3.
20. Taneepanichskul S, Reinprayoon D, Jaisamrarn U. Effects of DMPA on weight and blood pressure in long-term acceptors. Contraception 1999;59:301-3.
21. Fahmy K, Khairy M, Allam G, et al. Effect of depo-medroxyprogesterone acetate on coagulation factors and serum lipids in Egyptian women. Contraception 1991;44:431-44.
22. American College of Obstetricians and Gynecologists. The use of hormonal contraception in women with coexisting medical conditions. Practice Bulletin 18. Washington, DC: American College of Obstetricians and Gynecologists; 2000:1-14.
23. Sorensen MB, Collins P, Ong PJ, et al. Long-term use of contraceptive depot medroxyprogesterone acetate in young women impairs arterial endothelial function assessed by cardiovascular magnetic resonance. Circulation 2002;106:1646-51.
24. Graff-Iversen S, Tonstad S. Use of progestogen-only contraceptives/ medications and lipid parameters in women age 40 to 42 years: results of a population-based cross-sectional Norwegian Survey. Contraception 2002;66:7-13.
25. Cannegieter SC, Torn M, Rosendaal FR. Oral anticoagulant treatment in patients with mechanical heart valves: how to reduce the risk of thromboembolic and bleeding complications. J Intern Med 1999;245:369-74.
26. Jamal A, Mesdaghinia S. Ruptured corpus luteum cysts and anticoagulant therapy. Int J Gynaecol Obstet 2002;76:319-20.
27. Westhoff C. Bone mineral density and DMPA. J Reprod Med 2002;47(9 Suppl.):795-9.
28. van Eijkeren MA, Christiaens GC, Geuze HJ, et al. Effects of mefenamic acid on menstrual hemostasis in essential menorrhagia. Am J Obstet Gynecol 1992;166:1419-28.